Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
Revue Des Maladies Respiratoires
|
February 22, 2008
[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]
D Moro-Sibilot, F Barlesi, J F Timsit, et al.
ESMO Open
|
January 4, 2025
Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers
J-Y Blay, M Brahmi, A Dufresne, et al.
British Journal of Cancer
|
August 14, 2003
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)
R Bugat, A Bataillard, T Lesimple, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2007
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
R Rosell, G Robinet, A Szczesna, et al.
ESMO Open
|
July 24, 2025
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis
K Amrane, B Cabarrou, G Justeau, et al.
Targeted Oncology
|
August 29, 2015
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study
J B Auliac, C Fournier, C Audigier Valette, et al.
ESMO Open
|
June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort
Q D Thomas, X Quantin, P Lemercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
A J Schoenfeld, S J Antonia, M M Awad, et al.
ESMO Open
|
January 30, 2021
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
P Heudel, S Chabaud, D Perol, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
Revue Des Maladies Respiratoires
|
February 22, 2008
[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]
D Moro-Sibilot, F Barlesi, J F Timsit, et al.
ESMO Open
|
January 4, 2025
Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers
J-Y Blay, M Brahmi, A Dufresne, et al.
British Journal of Cancer
|
August 14, 2003
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)
R Bugat, A Bataillard, T Lesimple, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2007
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
R Rosell, G Robinet, A Szczesna, et al.
ESMO Open
|
July 24, 2025
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis
K Amrane, B Cabarrou, G Justeau, et al.
Targeted Oncology
|
August 29, 2015
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study
J B Auliac, C Fournier, C Audigier Valette, et al.
ESMO Open
|
June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort
Q D Thomas, X Quantin, P Lemercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
A J Schoenfeld, S J Antonia, M M Awad, et al.
ESMO Open
|
January 30, 2021
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
P Heudel, S Chabaud, D Perol, et al.
Page
of 6